Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 versus placebo for renal angiomyolipoma in TSC or sporadic LAM
NL-OMON37228Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in kidney angiomyolipoma (AML), tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) comparing RAD001 with Placebo (2 arms). Primary endpoint: Angiomyolipoma response rate. Started May 2010; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
kidney angiomyolipoma (AML)tuberous sclerosis complex (TSC)lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NL-OMON37228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37228.